Holen Sie sich die Stockscreener-App
17.28
1.20%
-0.21
Handel nachbörslich:
17.28
Schlusskurs vom Vortag:
$17.49
Offen:
$17.47
24-Stunden-Volumen:
608.24K
Relative Volume:
0.83
Marktkapitalisierung:
$1.41B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-4.0659
EPS:
-4.25
Netto-Cashflow:
$-168.82M
1W Leistung:
+4.60%
1M Leistung:
+17.55%
6M Leistung:
-6.34%
1J Leistung:
+5.75%
1-Tages-Spanne:
$16.80
$17.62
1-Wochen-Bereich:
$16.57
$18.44
52-Wochen-Spanne:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.28 | 1.43B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
How does Viridian Therapeutics Inc. compare to its industry peersGet real-time alerts on high-potential stocks - jammulinksnews.com
What institutional investors are buying Viridian Therapeutics Inc. stockInvest smarter with daily trading signals - jammulinksnews.com
What makes Viridian Therapeutics Inc. stock price move sharplyAchieve rapid portfolio growth with expert help - jammulinksnews.com
Intrinsic Value of Viridian Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree Stock Selection with 300% Return - Newser
Insider Buying and Strategic Alignment at Viridian Therapeutics: A Signal for Biotech Investors - AInvest
Viridian Therapeutics Inc. Stock Support and Resistance Levels You Should Know - Newser
Key External Factors That Drive Viridian Therapeutics Inc. Stock Price MovementsDaily Gain Forecast - Newser
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Competitive Positioning of Viridian Therapeutics Inc.: Is It Leading or LaggingReal Time Alert Service - Newser
What drives Viridian Therapeutics Inc. stock priceFree Stock Movement Tracking - PrintWeekIndia
Viridian Therapeutics Inc. Stock Analysis and ForecastTremendous return rates - Autocar Professional
What analysts say about Viridian Therapeutics Inc. stockLightning-fast growth - PrintWeekIndia
How Viridian Therapeutics Inc. stock performs during market volatilityMarket Ready Callouts - Newser
Is Viridian Therapeutics Inc. a good long term investmentExplosive trading opportunities - Autocar Professional
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
Why Viridian Therapeutics Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
Teacher Retirement System of Texas Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
(VRDN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viridian Therapeutics Inc-Aktie (VRDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Jun 09 '25 |
Option Exercise |
7.80 |
1,600 |
12,480 |
3,447,413 |
| Beetham Thomas W. | Chief Operating Officer |
Sep 27 '24 |
Buy |
23.41 |
5,000 |
117,050 |
6,000 |
| Mahoney Stephen F. | President and CEO |
Sep 27 '24 |
Buy |
23.33 |
21,400 |
499,262 |
21,400 |
| Fairmount Funds Management LLC | Director |
Sep 13 '24 |
Buy |
18.75 |
1,600,000 |
30,000,000 |
3,445,813 |
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):